11/3/2026

speaker
Paul
Conference Operator

Welcome to the Ardelyx Third Quarter 2026 Earnings Call. All participants will be in a listen-only mode. I would now like to turn the conference over to Lisa Caperelli, SVP, Investor Relations and Corporate Communication. Lisa, you may begin.

speaker
Lisa Caperelli
SVP, Investor Relations and Corporate Communication

Thank you, Paul. Good afternoon and welcome to our Third Quarter 2026 Financial Results and Business Update Call. Earlier today, we issued our earnings release, which can be found on the investor section of our website at ardelyx.com. Slides that accompany today's call can also be found on our website. On today's call, I'm joined by Mike Raab, President and CEO of Ardelyx, and Sue Hohenleitner, our Chief Financial Officer. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties that may cause our actual results to differ materially from those expressed or implied, including those described in our annual report on Form 10-K, our quarterly report on Form 10-Q, which was filed today, and from time to time in our other documents filed with the SEC. These forward-looking statements speak only as of today's date, and while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. I will now pass the call over to Mike. Mike?

speaker
Mike Raab
President and Chief Executive Officer

Thank you, Lisa. Good afternoon, everyone, and thank you for joining us today. Our Deluxe is a company focused on developing and commercializing innovative medicines. And today, with Absrel and Exposa, we have two first-in-class medicines that in the third quarter generated over $125 million in revenue, up 19% from a year ago. With a strengthened financial position and robust patent portfolio, our products are well positioned for significant long-term growth. Our focus is now to leverage that foundation and to build a pipeline to create long-term value. Our third quarter's performance bolsters our confidence as we focus on executing on our priorities, accelerating the growth of Ibsrella, maintaining Xfose's momentum, building and expanding our pipeline, and delivering strong financial results. Starting with Ibsrella, in Q3, Ibsrella generated revenue of $96.3 million, representing 23% year-over-year growth. HCP confidence in Ibsrella remains high, with demand reaching all-time highs as the number of total riders, Total Prescriptions and Market Share continues to grow. This growth supports our full-year guidance and reinforces our long-term view of achieving a billion dollars in annual revenue. Critical to that is our ongoing work to thoughtfully eliminate the payer friction HCPs and patients experience when first starting Azarella. In our efforts to alleviate some of this friction in the third quarter, we began to see progress that gave us confidence that these initiatives are beginning to take hold. As we've noticed in the past, Absrella is a promotionally sensitive brand and mid-year we expanded our sales force to increase reach and frequency to our target HCPs and continue to build the top of the funnel demand. In addition, we doubled our fuel reimbursement team to help HCPs navigate the prior authorization landscape. We're also continuing our efforts to transition riders to utilize the Absrella pharmacy network as we know that when the IPN is utilized, patients experience two to three higher fulfillment rates, faster fill times, and at least one additional refill per patient on an annual basis. We will continue to assess all tools at our disposal to streamline the prior authorization process, such as how best to leverage digital and AI tools. Our teams are executing at a high level, translating into notable results with total prescriptions growing. On September 1st, we embarked on a highly targeted effort to raise awareness of Adrella with IVFC patients and launched our first direct-to-consumer ad. This highly targeted ad has a clear call to action and is intended to reach more than 10 million people through outlets such as Netflix, Hulu, Prime Video, and Disney+. In the taste testing phase of the ad with IBSC patients, 91% of them said that they would ask their doctor if Adrella was right for them. And in a short time, we've seen that the campaign has delivered meaningful impressions and is driving an increase in traffic to our consumer-focused website. These are early positive indicators, and we continue to monitor how this increased awareness translates into new patient starts. As you know, the IBSC market is very large. Over 7 million prescriptions are written for IBSC-approved medications per year, and more than 70% of patients continue to experience persistent symptoms, which is developing an important alternative for millions of dissatisfied IBSC patients. In addition to providing benefits to IVSE patients, our real-world data demonstrated that there is also the potential of generating significant savings in healthcare services for IVSE patients when they are treated with Ibsrella. A few weeks ago, at the American College of Gastroenterology Annual Scientific Meeting, we presented real-world data showing that when Ibsrella, when on Ibsrella, GI-related healthcare resources utilization drops, primarily driven by fewer doctor visits and labs. Taken together, Ibsrella not only provides symptom relief for IBSC patients, but may also reduce broader healthcare resource burden when associated with the disease. The fundamentals of the Ibsrella business remain very strong, and by staying focused on execution and improving patient access, we are positioned to drive continued adoption and create meaningful benefits for patients. Now, moving on to Exfosa. Revenue in Q3 was $29.2 million, representing 7% year-over-year growth, and we continue to see growth in paid prescriptions of 22% compared to the same quarter in 2025. The need for exposure remains high. In the United States, there are more than 550,000 adults with CKD on dialysis, with more than 80% of them requiring treatment for hyperphosphatemia, and yet nearly 70% of those patients struggle to reach and maintain target phosphorus levels. A few weeks ago at the American Society of Nephrology Kidney Week, we presented real-world evidence supporting Xposa's ability to consistently reduce serum phosphate. We also presented data highlighting the difficulty of managing hyperphosphatemia and the serious mortality morbidity associated with the cumulative phosphate burden. Together, these findings continue to reinforce the need for Xposa, a differentiated treatment that can help dialysis patients reach and maintain target phosphorus levels. As we've discussed before, the dialysis reimbursement environment is complex, and we are taking thoughtful and measured approach to help ensure that Xposa continues to be a positive contributor. Now, pivoting to our pipeline. Tanapinor is our foundation and will enable us to grow our pipeline. Our most advanced program with Azrel is our Excel Phase III clinical trial in patients with chronic idiopathic constipation, or CIC. Today, we announced that we have fully enrolled the trial ahead of schedule. The interest and pace of enrollment in the trial underscores the enthusiasm on the part of treating physicians for a new option for their patients experiencing the significant burden of CIC. Our confidence in the success of it with Israel and CIC patients is, in large part, based on data from our IBSC clinical development program. Patients with CIC and IBSC have overlapping symptoms. We believe that expanding the use of Azrella to CIC will provide an additional option for patients currently underserved by their CIC treatments. In October, we convened a medical advisory board of HCPs to elicit their feedback on the CIC treatment landscape and our phase three trial design. Three things stood out from that discussion that I'd like to share with you. First, the need is real, as CIC patients cycle through multiple over-the-counter products seeking care, and like IVSC patients, often arrived treatment experience. Second, there is a solid clinical rationale. CIC and IVSC overlap substantially. And we believe that the clinical efficacy observed with CIC and IVSC could translate to patients with CIC. Third, the trial has been well received as evidenced by the faster than projected enrollment in the Excel trial. We are encouraged by the progress we've made and look forward to reporting top line results in the second half of 2027. Finally, we are in a strong financial position with our $285 million of cash with our revenue funding our operations and supporting our path to profitability in 2027. And with that, I will now turn the call over to Sue to discuss the quarter's financials in detail. Sue?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation